Aurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New
York
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH;TSX:AUP) today announced it will host a Lupus Nephritis expert breakfast on Thursday,
August 4th from 8:00am to 9:30am EDT in New York.
The topics of the presentations will include current treatments for Lupus Nephritis, its disease burden, as well as
pharmacoeconomic and pricing dynamics for new products for less common diseases in the US market place. The company will also take
this opportunity to review in further detail the most recent proof of concept AURION study data, and the Phase IIb AURA-LV study
design.
The meeting will feature the following speakers:
|
|
|
Dr. Amit Saxena, Assistant Professor at the Department of Medicine at NYU Langone Medical
Center.
|
|
Dr. Doug Paul, PharmD, PhD and Adjunct Assistant Professor at the University of Mississippi School
of Pharmacy.
|
|
Mr. Robert Huizinga, VP of Clinical Affairs,Aurinia Pharmaceuticals.
|
|
Mr. Charles Rowland, CEO, Aurinia Pharmaceuticals.
|
The event is intended for investors, sell-side analysts, and business development professionals. If you would like to attend in
person, please contact Mac MacDonald at 212-915-2567 or via e-mail at Mac@LifeSciAdvisors.com to reserve a place.
A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20160804/reg.jsp and the Investors section of the Company’s website at http://www.auriniapharma.com/dnn/ForInvestors/Webcasts.aspx.
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. The fully-enrolled Phase 2b AURA-LV
clinical trial is evaluating the efficacy of its lead drug, voclosporin, as a treatment for active LN. LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening
condition.
Voclosporin is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,000
patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI
approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and
pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat
dosing.
About Voclosporin
Voclosporin is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,000
patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI
approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and
pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat
dosing.
About AURA:
The AURA–LV study or “Aurinia Urine Protein Reduction in Active Lupus Nephritis Study” is an adequate and well-controlled
clinical trial that enrolled 265 patients and is being conducted in over 20 countries worldwide. This trial will compare the
efficacy of voclosporin against placebo in achieving remission in patients with active lupus nephritis. The AURA-LV study is
designed to demonstrate that voclosporin can induce a rapid and sustained reduction of proteinuria in the presence of extremely low
steroid exposure. It will compare two dosage groups of voclosporin (23.7mg and 39.5mg) compared to placebo, with all patients
receiving mycophenolate mofetil (MMF) and oral corticosteroids as background therapy. There will be a primary analysis to determine
complete remission at week 24 (confirmed at 26 weeks) and various secondary analyses at week 48 which include biomarkers and
markers of non-renal SLE.
About AURION:
The AURION study or “Aurinia Early Urinary Protein Reduction Predicts Response Study” is an open label, exploratory study being
conducted in multiple sites in Malaysia to assess the short term predictors of response using voclosporin (23.7mg) in combination
with mycophenolate mofetil and oral corticosteroids in patients with active lupus nephritis. This study will examine biomarkers of
disease activity at 8 weeks and their ability to predict response at 24 and 48 weeks.
We seek Safe Harbor.
Aurinia Pharmaceuticals Inc.
Celia Economides, 917-941-9059
Associate Vice-President Communications & Advocacy
ceconomides@auriniapharma.com
or
Renmark Financial Communications Inc.
Barry Mire,416-644-2020
bmire@renmarkfinancial.com
or
Laura Welsh, 514-939-3989
lwelsh@renmarkfinancial.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160728006740/en/